Revenue Recognition (Tables)

3 Months Ended

Mar. 31, 2022

Revenue from Contract with Customer [Abstract]

Disaggregation of revenue

Segment information is as follows (in thousands):

	Three Months Ended March 31, 2022						Three Months Ended March 31, 2021
	Performance Enzymes		Novel Biotherapeutics		Total		Performance Enzymes		Novel Biotherapeutics		Total
Major products and service:
Product revenue	$	30,690	$	—	$	30,690	$	10,226	$	—	$	10,226
Research and development revenue	2,409		2,241		4,650		4,003		3,803		7,806
Total revenues	$	33,099	$	2,241	$	35,340	$	14,229	$	3,803	$	18,032
Primary geographical markets:
Americas	$	2,553	$	1,179	$	3,732	$	2,871	$	2,058	$	4,929
EMEA	3,065		1,062		4,127		4,537		1,745		6,282
APAC	27,481		—		27,481		6,821		—		6,821
Total revenues	$	33,099	$	2,241	$	35,340	$	14,229	$	3,803	$	18,032

Contract with customer

The following table presents balances of contract assets, unbilled receivables, contract costs, and contract liabilities (in thousands):

	March 31, 2022		December 31, 2021
Contract assets	$	9,751	$	4,557
Unbilled receivables	$	9,584	$	8,558
Contract costs	$	46	$	56
Contract liabilities: deferred revenue	$	5,068	$	6,335

We recognized the following revenues (in thousands):

	Three Months Ended March 31,
Revenue recognized in the period for:	2022		2021
Amounts included in contract liabilities at the beginning of the period:
Performance obligations satisfied	$	1,094	$	862
Changes in the period:
Changes in the estimated transaction price allocated to performance obligations satisfied in prior periods	215		24
Performance obligations satisfied from new activities in the period - contract revenue	34,031		17,146
Total revenues	$	35,340	$	18,032

Performance obligation, expected timing of satisfaction

The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting periods. The estimated revenue does not include contracts with original durations of one year or less, amounts of variable consideration attributable to royalties, or contract renewals that are unexercised as of March 31, 2022.The balances in the table below are partially based on judgments involved in estimating future orders from customers subject to the exercise of material rights pursuant to respective contracts as of March 31, 2022 (in thousands):

	Remainder of 2022		2023		2024		2025 and Thereafter		Total
Product revenue	$	60	$	67	$	100	$	2,740	$	2,967
Research and development revenue	1,254		847		—		—		2,101
Total revenues	$	1,314	$	914	$	100	$	2,740	$	5,068